The most common symptoms, which are mild and temporary, include abdominal pain, loose stools, and increased flatulence (mostly associated with oral supplementation)
Clinical Evidence From Semaglutide Weight Loss Trials The SUSTAIN-6 cardiovascular outcomes trial, which followed over 3,000 patients with type 2 diabetes, documented systolic blood pressure reductions averaging 3.5 mmHg in the semaglutide group compared to placebo
This inconsistency is the defining feature of DSIP sleep research
Numerous metabolic and glucose markers, such as HbA1c, fasting insulin, glucose, and uric acid, are also tested, offering insights into blood sugar regulation and metabolic balance
Tham LS, Schneck KB, Geiser JS, Posada M, Dickinson G